Expression of the Epstein-Barr virus (EBV)-encoded latent membrane protein 2A (LMP2A) in EBV-associated nasopharyngeal carcinoma
Expression of the Epstein-Barr virus (EBV)-encoded latent membrane protein 2A (LMP2A) in EBV-associated nasopharyngeal carcinoma
复制标题
DOI：
10.1002/path.1569
复制
发表时间：
2004-06-01
影响因子：
7.3
通讯作者：
Niedobitek, G
中科院分区：
文献类型：
--
作者：
Heussinger, N;Büttner, M;Niedobitek, G
EB病毒（EBV）与几乎所有未分化鼻咽癌（NPC）病例相关，并已被归类为I组致癌物。EB病毒除了在鼻咽癌的发病机制中发挥重要作用外，由于肿瘤细胞中表达的病毒基因数量有限，因此也为鼻咽癌的免疫治疗提供了一个可能的靶点。EB病毒编码的潜伏膜蛋白2A（LMP2A）被认为是一个有前途的目标，因为它提供了EB病毒特异性T细胞识别的表位。免疫组化结果显示，LMP2A在35例鼻咽癌活检组织中有16例（45.7%）肿瘤细胞表达。这一发现提供了进一步的证据，表明NPC肿瘤细胞可能对针对LMP2A的细胞毒性T细胞的溶解敏感，并应鼓励努力开发用于治疗NPC的免疫方法。版权所有（C）2004大不列颠和爱尔兰病理学会。出版社：John Wiley Sons，Ltd
The Epstein-Barr virus (EBV) is associated with virtually all cases of undifferentiated nasopharyngeal carcinoma (NPC) and has been classified as a group I carcinogen. In addition to its potential role in the pathogenesis of NPC, EBV also provides a possible target for immunotherapy of NPC, since a limited number of viral genes are expressed in the neoplastic cells. The EBV-encoded latent membrane protein 2A (LMP2A) is considered a promising target since it provides epitopes recognized by EBV-specific T-cells. Using immunohistochemistry, the present study shows that LMP2A is expressed at the protein level in the neoplastic cells of 16 of 35 (45.7%) NPC biopsies. This finding provides further evidence suggesting that NPC tumour cells may be susceptible to lysis by cytotoxic T-cells directed against LMP2A and should encourage efforts to develop immunotherapeutic approaches for the treatment of NPC. Copyright (C) 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley Sons, Ltd.